Clene Nanomedicine, Inc. — Form D
Clene Nanomedicine, Inc. of SALT LAKE CITY, UT, a company, filed a Form D exempt-offering notice with the SEC on 2020-07-13. The offering totals $7.0M, of which $6.1M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2020-07-13
- Form: D
- Accession: 0001817741-20-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $7.0M
- Amount sold: $6.1M
- Remaining: $875K
- Minimum investment: $25K
- Investors: 12
- Date of first sale: 2020-02-07
- Security types: debt
- Revenue range: Decline to Disclose
- SEC file number: 021-370864
Issuer
- Name: Clene Nanomedicine, Inc.
- CIK: 0001817741
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Address: 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY, UT, 84121
- Phone: 801-676-9695
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Ryan Lund | Director | Salt Lake City, UT |
| John Stevens | Director | New York, NY |
| Alison Mosca | Director | Salt Lake City, UT |
| Shalom Jacobovitz | Director | Salt Lake City, UT |
| Reed Wilcox | Director | Salt Lake City, UT |
| Chad Young | Director | Salt Lake City, UT |
| David Lisonbee | Director | Salt Lake City, UT |
| Robert Gay | Director | Salt Lake City, UT |
| Rob Etherington | Director | Salt Lake City, UT |
| Rob Etherington | Executive Officer | Salt Lake City, UT |
Other filings by this issuer (1)
More